Series A · Raised $12.6M · Jul 22, 2026announcement ↗
Brenus Pharma
Backed by
BiotechLyon, Francebrenus-pharma.com ↗
What they do
Brenus Pharma, based in Lyon, develops off-the-shelf in vivo immunotherapies for hard-to-treat solid tumors. Its platform uses engineered, inactivated tumor cells to expose cancer-associated antigens and stimulate immune responses against heterogeneous and treatment-resistant tumors.
Hiring outlook
A $12.6 million Series A in biotech suggests continued hiring in cancer biology, immunology, translational research, process development, and clinical or regulatory operations. The company may also add manufacturing and quality specialists as its candidates move toward clinical development.
Open roles
Pre-flood window open
Nothing posted yet since the raise, which is exactly when a direct, well-aimed email to a founder beats every job portal. When the postings go up, so does the competition.
Get founders like this to reach you →